The legislation gives companies more wiggle room, but most of them don't want it and are not going to use it. Patients are "no better off today with Right to Try than [they were] yesterday," says Arthur Caplan, head of medical ethics at NYU School of Medicine. In other pharma news: lawmakers want companies to develop new antibiotics but they're not offering any extra incentives for them to do so; Sen. Claire McCaskill (D-Mo.) wants to increase transparency over payments to patient advocacy groups; tips on getting around pharmacists' gag rule; and more.

from Kaiser Health News https://ift.tt/2Jp4N9Q

Related Posts:

0 comments:

Post a Comment

Popular Posts